Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chelsea prices $35 million offering to fund droxidopa programme

This article was originally published in Scrip

Executive Summary

Chelsea Therapeutics is raising $35 million in a fully underwritten public offering of 8.75 million shares of its common stock. As announced on 18 February, the price to the public is $4 per share, and the underwriters, which include Deutsche Bank Securities, Ladenburg Thalmann and Wedbush PacGrow Life Sciences, have agreed to purchase the shares from Chelsea at a price of $3.764 per share. Chelsea expects the net proceeds from the sale to be about $32.8 million.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts